Riluzole preserves brain endothelial integrity in ischemic stroke via SLC7A11-dependent GPX4 and HIF-1α/VEGFA
Haipeng Wang1, Ying Feng2, Wei Jiang1
1College of Biomedicine and Health, College of Life Science and Technology, Huazhong Agricultural University, Wuhan 430070, Hubei, China.
Abstract:
Riluzole, an FDA-approved neuroprotective agent, was investigated for its therapeutic potential in ischemic stroke. Transcriptomic profiling of human brain microvascular endothelial cells (hBMECs) subjected to oxygen-glucose deprivation/reperfusion (OGD/R) identified a pivotal role for the cystine/glutamate antiporter SLC7A11. We found that riluzole activates SLC7A11, thereby triggering a dual protective mechanism: it strengthens cellular antioxidant capacity by upregulating GPX4 while simultaneously enhancing proangiogenic signaling through the HIF-1α/VEGFA pathway. Consequently, riluzole attenuated OGD/R-induced endothelial injury and, in a mouse stroke model, reduced blood-brain barrier disruption and improved neurological outcomes. Our study reveals a previously unrecognized cerebrovascular protective mechanism of riluzole, establishing SLC7A11 as its key mediator. This SLC7A11-dependent dual-pathway action represents a substantive advance in understanding riluzole's therapeutic biology beyond its established roles in the central nervous system.
Related Concept Videos
Contact-dependent Signaling
Gap Junctions
In animal cells, gap junctions are formed...
The Integrated Rate Law: The Dependence of Concentration on Time
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
¹H NMR Signal Integration: Overview
Paracrine Signaling


